OverviewSuggest Edit

Molecular Templates is a biopharmaceutical company with a novel protein platform for the development of new therapeutics against cancer. The Company's lead drug candidate is MT-3724 that is in Phase II clinical trial for the treatment of relapsed diffuse large B-cell lymphoma, and Phase II clinical trial for treating non-Hodgkin’s lymphoma.
TypePublic
Founded2009
HQAustin, US
Websitemtem.com

Latest Updates

Employees (est.) (Jun 2019)72(+6%)
Revenue (FY, 2019)$22.3 M(+68%)
Share Price (Nov 2020)$10.3 (+2%)
Cybersecurity ratingAMore

Key People/Management at Molecular Templates

Eric Poma

Eric Poma

Director, Chief Executive Officer & Chief Scientific Officer
Michael Broxson

Michael Broxson

Director
Jonathan Lanfear

Jonathan Lanfear

VP and Global Head of Oncology & Neuroscience Business Development at Takeda Pharmaceuticals
Jason Kim

Jason Kim

President & Chief Operating Officer
David Hirsch

David Hirsch

Director
Roger Waltzman

Roger Waltzman

Chief Medical Officer
Show more

Molecular Templates Office Locations

Molecular Templates has offices in Austin and Georgetown
Austin, US (HQ)
9301 Amberglen Blvd #100
Georgetown, US (HQ)
111 W. Cooperative Way
Show all (2)

Molecular Templates Financials and Metrics

Molecular Templates Revenue

Molecular Templates's revenue was reported to be $22.27 m in FY, 2019
USD

Market capitalization (13-Nov-2020)

513.1m

Closing stock price (13-Nov-2020)

10.3

Cash (30-Sept-2020)

33.4m

EV

507.4m
Molecular Templates's current market capitalization is $513.1 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

62.0k5.9m12.5m14.7m76.9m3.4m13.3m22.3m

General and administrative expense

5.7m7.1m9.2m10.1m9.7m7.8m11.8m14.1m20.1m

R&D expense

24.4m18.8m29.3m35.8m40.3m16.6m9.5m30.2m50.5m

Operating expense total

30.1m25.9m38.5m46.0m50.0m24.4m21.2m44.3m70.6m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Revenue

252.0k1.8m1.8m2.9m3.2m3.2m3.7m3.7m3.7m3.7m3.7m3.7m3.0m648.0k482.0k1.4m6.8m7.0m5.4m3.6m

General and administrative expense

1.7m1.3m1.7m1.8m1.7m2.5m2.2m2.1m2.6m2.5m2.4m2.6m2.5m2.4m2.2m1.9m1.7m2.9m1.7m4.0m2.9m3.7m3.5m4.9m4.6m4.5m5.6m

R&D expense

5.1m6.5m5.7m2.9m4.0m6.5m8.0m6.4m9.7m8.7m8.9m10.7m10.1m8.1m6.0m4.0m3.5m1.6m1.1m2.5m6.7m7.7m8.3m8.5m10.2m15.2m20.6m

Operating expense total

6.8m7.8m7.4m4.7m5.8m9.0m10.1m8.4m12.3m11.1m11.3m13.3m12.6m10.5m8.3m5.9m5.2m4.4m2.8m6.5m9.6m11.4m11.8m13.4m14.8m19.8m26.3m
USDQ2, 2011

Financial Leverage

2.6 x
Show all financial metrics

Molecular Templates Cybersecurity Score

Cybersecurity ratingPremium dataset

A

94/100

SecurityScorecard logo

Molecular Templates Online and Social Media Presence

Embed Graph

Molecular Templates News and Updates

Molecular Templates, Inc. Reports Third Quarter 2020 Financial Results and Provides a Corporate Update

AUSTIN, Texas, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” “MTEM” or “the Company”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETB…

Molecular Templates Announces Presentations at the American Society of Hematology (ASH) 2019 Annual Meeting

AUSTIN, Texas, Dec. 09, 2019 (GLOBE NEWSWIRE) -- Molecular Templates, Inc., (Nasdaq: MTEM) a clinical-stage biopharmaceutical  company focused on the discovery and development of the Company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics, to…

Molecular Templates, Inc. Reports Third Quarter 2019 Financial Results

AUSTIN, Texas, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular,” “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of the company’s proprietary engineered toxin bodies (ETBs), which are differ…

Molecular Templates Blogs

Molecular Templates to Participate in Upcoming Virtual Investor Conferences

AUSTIN, Texas, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of the company’s proprietary engineered toxin bodies (ETBs), which are differentiated, tar…

Molecular Templates to Participate in September Virtual Investor Conferences

Molecular Templates to Participate in September Virtual Investor Conferences Content Import Thu, 09/03/2020 - 08:03 Molecular Templates to Participate in September Virtual Investor Conferences September 3, 2020 at 8:00 AM EDT This release is a backfill from a …

Molecular Templates, Inc. Reports Second Quarter 2020 Financial Results

Molecular Templates, Inc. Reports Second Quarter 2020 Financial Results Content Import Thu, 08/06/2020 - 16:31 Molecular Templates, Inc. Reports Second Quarter 2020 Financial Results August 6, 2020 at 4:30 PM EDT This release is a backfill from a News Wire …

Molecular Templates, Inc. Raises $43 Million in Gross Proceeds Through Its At-the-Market Facility

AUSTIN, Texas , July 20, 2020 (GLOBE NEWSWIRE) -- Molecular Templates , Inc. (Nasdaq: MTEM, “Molecular Templates,” “MTEM” or the “Company”), a clinical-stage biopharmaceutical company focused on the discovery and development of the Company’s proprietary targeted biologic therapeutics, engineered

Molecular Templates, Inc. Announces $45 Million Debt Financing From K2 HealthVentures

AUSTIN, Texas , May 22, 2020 (GLOBE NEWSWIRE) -- Molecular Templates , Inc. (Nasdaq: MTEM, “Molecular Templates,” “MTEM” or the “Company”), a clinical-stage biopharmaceutical company focused on the discovery and development of the Company’s proprietary targeted biologic therapeutics, engineered

New Data on Molecular Templates’ Engineered Toxin Bodies to be Presented at the American Association of Cancer Research (AACR) Virtual Annual Meeting II

New Data on Molecular Templates’ Engineered Toxin Bodies to be Presented at the American Association of Cancer Research (AACR) Virtual Annual Meeting II Content Import Fri, 05/15/2020 - 07:01 New Data on Molecular Templates’ Engineered Toxin Bodies to be Presented at the American Associati…
Show more

Molecular Templates Frequently Asked Questions

  • When was Molecular Templates founded?

    Molecular Templates was founded in 2009.

  • Who are Molecular Templates key executives?

    Molecular Templates's key executives are Eric Poma, Michael Broxson and Jonathan Lanfear.

  • How many employees does Molecular Templates have?

    Molecular Templates has 72 employees.

  • What is Molecular Templates revenue?

    Latest Molecular Templates annual revenue is $22.3 m.

  • What is Molecular Templates revenue per employee?

    Latest Molecular Templates revenue per employee is $309.3 k.

  • Who are Molecular Templates competitors?

    Competitors of Molecular Templates include ANA Therapeutics, Arietis Pharma and KMT Hepatech.

  • Where is Molecular Templates headquarters?

    Molecular Templates headquarters is located at 9301 Amberglen Blvd #100, Austin.

  • Where are Molecular Templates offices?

    Molecular Templates has offices in Austin and Georgetown.

  • How many offices does Molecular Templates have?

    Molecular Templates has 2 offices.